Brief: Neuren Pharmaceuticals Says Daybue Receives Marketing Authorization In Canada
17/10/2024 02:28
Oct 17 (Reuters) - Neuren Pharmaceuticals Ltd NEU.AX :
* DAYBUE (TROFINETIDE) RECEIVES MARKETING AUTHORIZATION IN
CANADA
Further company coverage: NEU.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neuren Pharmaceuticals
See all newsAustralia's Neuren set for weekly gain on FDA nod, drug forecast upgrade
Australia's Neuren Pharmaceuticals gains on upbeat FY trofinetide earnings outlook
Australia's Neuren Pharma rises as US FDA grants orphan tag for NNZ-2591
Strong partner sales propel Neuren Pharmaceuticals to top of Australia benchmark
Brief: Neuren Pharmaceuticals Says DAYBU Recommended For Approval In European Union